%0 Generic %A Rosendaal, Nicole T. A. %A E. Hendriks, Marleen %A Verhagen, Mark D. %A A. Bolarinwa, Oladimeji %A Sanya, Emmanuel O. %A Kolo, Philip M. %A Adenusi, Peju %A Agbede, Kayode %A van Eck, Diederik %A Tan, Siok Swan %A M. Akande, Tanimola %A Redekop, William %A Schultsz, Constance %A B. Gomez, Gabriela %D 2016 %T Outcomes in costs (US$ 2012) and DALYs averted for a cohort of 10,000 individuals. %U https://plos.figshare.com/articles/dataset/Outcomes_in_costs_US_2012_and_DALYs_averted_for_a_cohort_of_10_000_individuals_/3925617 %R 10.1371/journal.pone.0157925.t002 %2 https://plos.figshare.com/ndownloader/files/6143247 %K hypertension care %K finance CVD prevention care %K Kwara State Health Insurance %K sensitivity %K antihypertensive treatment %K Health Insurance Program Background High blood pressure %K SSA %K health insurance program %K strategy %K 10- year CVD risk %K Conclusions Hypertension care %K KSHI program %K disability-adjusted life year %K population-level hypertension screening %K DALY %K cost-effectiveness %K hypertension grade 1 %K grade 2 hypertension %K model %X

Outcomes in costs (US$ 2012) and DALYs averted for a cohort of 10,000 individuals.

%I PLOS ONE